BEIJING, Dec. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. , a leading provider of vaccines in China, today announced that it has received confirmation from Beijing Medicine Bidding Center that Sinovac's hepatitis A vaccine Healive was selected by the Beijing Centers For Diseases Control and Prevention (BJ CDC) pursuant to its tender process. As a result of the selection, Healive is one of two inactivated hepatitis A vaccines in pre- filled syringes that will be purchased by the Beijing CDC for its Hepatitis A vaccination program. The tender covers purchasing activities from 2007 to 2009. The selection is part of the governmental initiative to include hepatitis A in the China National Expanded Immunization Program.
Mr. Weidong Yin, Chairman, President and CEO, stated, "We are pleased to receive confirmation that Healive was selected by the Beijing CDC. The tender process evaluated the safety and efficacy profile of Healive, in conjunction with Sinovac's manufacturing capability and post sales service in order to supply the requisite doses over the next three years."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, and Japanese encephalitis. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
info@sinovac.comscarrington@theruthgroup.com jmccargo@theruthgroup.com
CONTACT: Helen G. Yang of Sinovac Biotech Ltd., +86-10-8289-0088 x871,
Fax: +86-10-6296-6910, info@sinovac.com; or Investors/Media: Stephanie
Carrington, +1-646-536-7017, scarrington@theruthgroup.com, or Janine
McCargo, +1-646-536-7033, jmccargo@theruthgroup.com, both of The Ruth
Group, both for Sinovac Biotech Ltd.
Web site: http://www.sinovac.com/
